Factors associated with 2009 monovalent H1N1 vaccine coverage: A cross sectional study of 1308 patients with psoriasis in France

Vaccine

Volumn 30, Issue 39, 2012, Pages 5703-5707

  Sbidian, Emilie ^a,b,c   Tubach, Florence ^d,e,f   Pasquet, Blandine ^d,e,f   Paul, Carle ^g   Jullien, Denis ^h   Sid Mohand, Dalila ⁱ   Bachelez, Hervé ^e,j,k  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c LIC EA439   (France)

^d BICHAT HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f INSERM   (France)

^g UNIVERSITÉ DE TOULOUSE   (France)

^h HÔTEL DIEU   (France)

ⁱ Association Pour la Lutte Contre le Psoriasis (APLCP)   (France)

^j SAINT LOUIS HOSPITAL   (France)

^k HÔPITAL NECKER ENFANTS MALADES   (France)

more..

Author keywords

2009 monovalent H1N1 vaccine; Psoriasis; Vaccination

Indexed keywords

CYCLOSPORIN; ETRETIN; HEPATITIS B VACCINE; INFLUENZA VACCINE; METHOTREXATE; PNEUMOCOCCUS VACCINE;

2009 H1N1 INFLUENZA; ADULT; ARTICLE; CHRONIC DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DATA ANALYSIS; DEMOGRAPHY; FEMALE; FRANCE; HEALTH ASSESSMENT QUESTIONNAIRE; HEPATITIS B; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PHOTOTHERAPY; PNEUMOCOCCAL INFECTION; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; RISK; SEASONAL VARIATION; SOCIAL ASPECT;

ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; FRANCE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PSORIASIS; VACCINATION;

EID: 84864912883     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.014     Document Type: Article

References (18)

1. WHO Recommendations on pandemic (H1N1) 2009 vaccines 2009, World Health Organization.
2. Haut Conseil de la Santé Publique Guidance on health priority setting for the use of pandemic vaccines against A(H1N1)v influenza virus 2009.
3. Bone A., Guthmann J.P., Nicolau J., Levy-Bruhl D. Population and risk group uptake of H1N1 influenza vaccine in mainland France 2009-2010: results of a national vaccination campaign. Vaccine 2010, 28(51):8157-8161.
4. Pathirana D., Ormerod A.D., Saiag P., Smith C., Spuls P.I., Nast A., et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2010, 24(1):117-118.
5. Bachelez H., B.M. European and British recommendations on the role of biologic interventions in moderate to severe psoriasis. Ann Dermatol Venereol 2011, 138(2 (Suppl. 2)):H14-H17.
6. Gluck T., Muller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis 2008, 46(9):1459-1465.
7. Institut. National de Veille Sanitaire Calendrier des vaccinations et recommandations vaccinales 2009 selon l'avis du Haut Conseil de la Santé Publique. Bull Epidémiol Hebdomadaire 2009, 16-17:147-162.
8. Rahier J.F., Moutschen M., Van Gompel A., Van Ranst M., Louis E., Segaert S., et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) 2010, 49(10):1815-1827.
9. Localio A.R., Margolis D.J., Berlin J.A. Relative risks and confidence intervals were easily computed indirectly from multivariable logistic regression. J Clin Epidemiol 2007, 60(9):874-882.
10. Kroneman M.W., van Essen G.A., Tacken M.A., Paget W.J., Verheij R. Does a population survey provide reliable influenza vaccine uptake rates among high-risk groups? A case-study of The Netherlands. Vaccine 2004, 22(17-18):2163-2170.
11. Mangtani P., Shah A., Roberts J.A. Validation of influenza and pneumococcal vaccine status in adults based on self-report. Epidemiol Infect 2007, 135(1):139-143.
12. Martin L.M., Leff M., Calonge N., Garrett C., Nelson D.E. Validation of self-reported chronic conditions and health services in a managed care population. Am J Prev Med 2000, 18(3):215-218.
13. Nichol K.L., Korn J.E., Baum P. Estimation of outpatient risk characteristics and influenza vaccination status: validation of a self-administered questionnaire. Am J Prev Med 1991, 7(4):199-203.
14. Mac Donald R., Baken L., Nelson A., Nichol K.L. Validation of self-report of influenza and pneumococcal vaccination status in elderly outpatients. Am J Prev Med 1999, 16(3):173-177.
15. Cotte L., Voirin N., Richard C., Brochier C., Schlienger I., Lack P., et al. Factors associated with pandemic influenza A/H1N1 vaccine coverage in a French cohort of HIV-infected patients. Vaccine 2011, 29(34):5638-5644.
16. Vaux S., Van Cauteren D., Guthmann J.P., Le Strat Y., Vaillant V., de Valk H., et al. Influenza vaccination coverage against seasonal and pandemic influenza and their determinants in France: a cross-sectional survey. BMC Public Health 2011, 11:30.
17. Printza N., Roilides E., Kotsiou M., Zafeiriou D., Hatzidimitriou V., Papachristou F. Pandemic influenza A (H1N1) 2009-associated hemolytic uremic syndrome. Pediatr Nephrol 2011, 26(1):143-144.
18. Grippe A/H1N1 Recommandations communes de la SFD et de la SFR pour les patients atteints de psoriasis ou de rhumatisme inflammatoire traités par immunosuppresseurs ou biothérapies 2009.